454 DNA Sequencing
Overview
The GGF provides massively parallel DNA sequencing on the Roche FLX Genome Sequencer (aka 454) platform. The company 454 (http://www.454.com) developed the first massively parallel DNA sequencer brought to market. Roche subsequently acquired 454. The FLX Genome Sequencer is the 2nd generation instrument, and is capable of running the 2nd generation chemistry (known as “standard” or FLX chemistry) and the 3rd generation chemistry (known as “Titanium” or XLR chemistry). Please note – these chemistries are NOT interchangeable. GGF is currently only supporting Titanium chemistry.
We currently support the following protocols:
- genomic DNA sequencing
- cDNA/transcriptome sequencing
- MID-tags (20 currently, 151 possible)
- Amplicons (300 - 800 bp ONLY)
- BAC sequencing (this is not yet fully validated as of August 13, 2009)
We will support mate-pair libraries sometime in late 2009 and paired-end sequencing as soon as the reagents are available for Titanium chemistry (also late 2009). We will only support standard/FLX sequencing when specifically requested to do so (along with a financial commitment for purchase and use of the FLX sequencing reagents), but we will always recommend researchers use other facilities for this chemistry.
All institutions delivering high quality 454 data have long queues, ranging from many weeks to several months. We provide priority access to researchers from Georgia Academic institutions, and currently have a short queue.
